<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522716</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-cGVH</org_study_id>
    <nct_id>NCT01522716</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease</brief_title>
  <official_title>Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stockholm County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety and efficacy of mesenchymal stromal cells as
      treatment for steroid-refractory chronic graft-versus-host disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease activity according to National Institute of Health criteria</measure>
    <time_frame>Baseline to 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease activity as measured by histological examination</measure>
    <time_frame>Baseline to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-assessed disease activity and quality of life</measure>
    <time_frame>Baseline to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>21 months</time_frame>
    <description>Frequency of complications, infections and relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from steroids at 1 year after MSC treatment</measure>
    <time_frame>1 year after finishing treatment</time_frame>
    <description>Proportion of patients free from corticosteroids at 1 year after finishing MSC treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stromal cell treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stromal cells</intervention_name>
    <description>Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.</description>
    <arm_group_label>Mesenchymal stromal cell treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic graft-versus-host disease, grade moderate or severe despite at least 3 months
             treatment with calcineurin inhibitors and steroids OR

          -  Chronic graft-versus-host disease, grade moderate or severe, where full treatment with
             calcineurin inhibitors and steroids is impossible due to intolerable side-effects

        Exclusion Criteria:

          -  Active malignancy

          -  Fulfilling criteria for previously initiated study for treatment of chronic
             graft-versus-host disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hematology Center, Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>May 30, 2016</last_update_submitted>
  <last_update_submitted_qc>May 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Lena von Bahr</investigator_full_name>
    <investigator_title>Leg l√§kare</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

